Chief Business Officer

Chief Accounting Officer

Director

Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also conducting studies on L606, an investigational, liposomal formulation of treprostinil.

Institution	Shares	Value	Change
BlackRock	10,788,586	$860M	INCREASED
State Street	3,030,395	$242M	INCREASED
Caprock Group	1,409,759	$112M	INCREASED
Purewater Capital	379,924	$30M	INCREASED
BNY Mellon	372,434	$30M	INCREASED

Insider	Type	Shares	Value	Date
Jason Adair (Chief Business Officer)	SELL	688	$60K	2026-07-27
Dana Boyle (Chief Accounting Officer)	SELL	1,600	$140K	2026-07-27
Stephen M Bloch (Director)	SELL	3,600	$327K	2026-07-22
Stephen M Bloch (Director)	SELL	96,400	$9M	2026-07-22
Stephen M Bloch (Director)	SELL	14,562	$1M	2026-07-22

Liquidia Corporation Common Stock (LQDA) Ownership & Trading Activity

Top Institutional Holders

Recent Insider Trades